Alnylam Pharmaceuticals

Alright, here is the paraphrased text: SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a prominent independent biopharmaceutical company and the trailblazer in RNA interference (RNAi) therapeutics, an innovative method for treating diseases by “silencing” the genes responsible for causing or contributing to them. Established in 2002 by a team of distinguished researchers and biotech pioneers, Alnylam's efforts across more than two decades have produced the essential breakthroughs and advancements that enabled the field of RNAi therapeutics to exist. In 2018, our first commercial product, and the world's inaugural RNAi therapeutic, received approval. From that point, four additional Alnylam-developed medicines have gained approval, and we are actively engaged in developing new treatments for both rare and common conditions. We are a global, diverse organization of over 2,500 employees. We take pride in cultivating a fun, inclusive, and dynamic workplace that enables staff to reach their full potential. This is why we are regularly recognized as a top employer by The Boston Globe (2015-24), Science Magazine (2018-24), Fast Company (Best Workplaces for Innovators 2020-25), and LinkedIn (2024). Our headquarters are located in Cambridge, Massachusetts (U.S.), with additional offices across North America, Europe, Asia, and South America. Refer to our social media community guidelines: https://bit.ly/2FcRhJy. Important: If you need to report an adverse event or product complaint, reach out to medinfo@alnylam.com, or call us at the following numbers: for North America, 877.ALNYLAM (877.256.9526); for Europe, +31 20 369 7861.